Barclays has initiated coverage on Bloom Energy (NYSE: BE) with an 'Equal Weight' rating and a $153 price target, citing strong fundamentals but suggesting the market has already priced in its near-term growth trajectory, particularly from AI data center demand.
Amid market volatility, these three companies offering yields above 4% present a compelling case for income-focused investors, backed by strategic pivots and resilient business models.
A surge in housing supply, particularly across Sun Belt states, is creating prime conditions for homebuyers, with new research highlighting metros where inventory levels tip the scale in the buyer's favor.
While Virco Mfg. Corporation's stock has declined nearly 10% over the past quarter, a deeper look at its financials—particularly its high profit reinvestment and strong earnings growth—suggests underlying strength that the market may be overlooking.
New analysis from NRC Health reveals that integrating real-time patient sentiment tools like Net Promoter Score with traditional HCAHPS surveys can accelerate improvements in care quality and directly impact Medicare reimbursements under value-based programs.
Krones AG (ETR:KRN) has seen its stock price climb 11% in the past quarter. Analysis points to robust fundamentals, particularly a healthy Return on Equity (ROE) of 14%, as a key driver behind the market's bullish sentiment and the company's impressive earnings growth trajectory.
RBC Capital has reaffirmed its confidence in Ascendis Pharma, raising its price target following the company's ambitious 2026 strategic goals, which hinge on sustained momentum for its lead therapy and significant long-term revenue targets.
ResMed reports robust revenue and margin expansion in its fiscal Q2 2026, driven by strong device and mask sales. Management highlights strategic investments in AI-powered patient tools and views GLP-1 medications as a potential catalyst for future demand.
Parker-Hannifin posts record-breaking Q2 fiscal 2026 results, fueled by robust organic growth and margin expansion, particularly in aerospace. The industrial giant raises full-year guidance and details strategic progress on its planned acquisition of Filtration Group Corporation.
Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.
Bank of America has upgraded Apellis Pharmaceuticals (APLS) to 'Buy,' citing robust early adoption of its drug Empaveli and significant undervaluation of its potential in treating rare kidney diseases, despite a more cautious outlook from Wells Fargo.
ResMed Inc. reports an 11% revenue surge for its second fiscal quarter, driven by robust mask sales and strategic acquisitions, while navigating competitive pressures and capitalizing on emerging healthcare trends.
Amidst global market turbulence, a new screen reveals a significant number of Asian stocks are trading below their intrinsic value, with discounts as high as 26.4%. We examine three standout companies from South Korea, Thailand, and Japan that appear poised for a potential re-rating.
Proposed flat payment rates for 2027 by CMS intensify margin pressures on Medicare Advantage insurers like Clover Health, raising investor concerns about cost management and growth prospects in a tightening regulatory landscape.
The alternative investment giant reported its strongest annual results in four decades, fueled by a surge in fundraising to $240 billion. Executives pointed to early signs of a reopening in deal activity and IPO markets, setting the stage for increased asset sales in 2026.
As Insmed prepares to unveil key data for its TPIP program at a major medical congress, fresh analyst coverage highlights the treatment's potential to reshape the company's future. Amidst a volatile stock performance, investors are weighing high-growth prospects against persistent financial risks.
While a seven-figure nest egg is a common retirement goal, financial experts caution that its sufficiency hinges on withdrawal strategies, lifestyle expectations, and supplemental income.
Amid a volatile market for mining stocks, Ramelius Resources stands out with a consistently high Return on Capital Employed (ROCE) of 30%, significantly outpacing its industry peers and fueling its multi-bagger potential.
Two Stanford graduate students have raised $2 million to launch Breakthrough Ventures, a nationwide accelerator designed to fund and mentor student-founded companies, addressing the historic lack of capital and networks for young entrepreneurs.
A 25-year-old Johnstown woman faces 18 felony counts, including arson endangering lives, after investigators say she intentionally set a duplex fire that forced residents to leap from second-story windows to escape.
